Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Games online, dress up games for free.
Popular Articles
Benefits Of Grapefruit

It's Official: No Senate Vote On Health Reform Before Recess
Senate Majority Leader Harry Reid Thursday said the Senate will be unable to pass health care reform before it leaves for its August recess, which will likely result in changes to the shape of the final bill, The Washington Post reports.
generic viagra online
Increasing Costs In Cancer Care Are A Growing Factor In Decision-Making For Patients, Physicians, Society
When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment"s medical benefits versus its possible side effects for the patient. Increasingly, however, as the already high costs of cancer care continue to rise, a full view of the patient"s welfare must also take into account the economic impact of the treatment on the patient and his or her family.
News of the day
Goal Of Good Quality Medicines Advanced By New USP Agreement With 9 ASEAN Countries
Furthering its mission to improve the quality of medicines worldwide, the U.S. Pharmacopeial (USP) Convention has signed a cooperative agreement with nine countries belonging to the Association of Southeast Asian Nations (ASEAN). In a drive to strengthen capacities and certification status of national drug quality control laboratories, officials from Cambodia, Laos, Myanmar, Singapore, Vietnam, Indonesia, Malaysia, the Philippines and Thailand had formed an ASEAN Reference Materials Working Group (ARMWG) to focus on modern, international measurement standards for medicines in the region. The agreement with USP is the culmination of discussions that started in 2008 with the aim of improving the production, precision and quality of ASEAN Reference Substances (ARS).
Health Insurance

Drug Manufacturer Receives Fast Track Designation From FDA

Pharmaceutical firm Biogen Idec announced that the American drug watchdog the Food and Drug Administration (FDA) has granted Fast Track designation for its multiple sclerosis (MS) drug PEGylated interferon beta-1a (BIIB017). The company is currently enrolling patients in a global Phase III study evaluating the effectiveness and safety of either bi-weekly or once-monthly injections of the therapy in people with relapsing remitting MS. If the trial reports promising results it means that people could inject their medication less often without sacrificing effectiveness. The FDA"s Fast Track program is designed to speed up the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Biogen Idec plans to enrol more than 1,200 patients with relapsing remitting MS in the Phase III, randomized, double-blind, placebo-controlled trial called ADVANCE designed to evaluate the effectiveness and safety of PEGylated interferon beta-1a. Patients interested in finding out more about the ADVANCE trial should speak to their neurologist or email ADVANCEstudy@biogenidec.com Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009